长效药物市场到2033年将达到133亿美元，在持续给药技术和慢性病管理进步的推动下不断扩张

Long-Acting Drugs Market to Reach US$ 13.3 Billion by 2033 Expands Amid Advances in Sustained Drug Delivery and Chronic Disease Management - Persistence Market Research

PR Newswire 等信源发布 2026-06-30 22:43



可切换为仅中文







LONDON

伦敦

，

June 30, 2026

2026年6月30日

/PRNewswire/ -- The global

/美通社/ -- 全球

long-acting drugs market

长效药物市场

is growing steadily, expected to be valued at around US$ 7.2 billion in 2026 and projected to reach US$ 13.3 billion by 2033, with a CAGR of 8.9% in the coming years. This expansion comes from the increasing prevalence of chronic diseases, rising demand for patient-friendly therapies, and rapid innovation in sustained-release drug delivery systems.

稳步增长，预计2026年市场规模将达到约72亿美元，并有望在2033年达到133亿美元，未来几年的复合年增长率（CAGR）为8.9%。这一扩张源于慢性疾病患病率的不断上升、对患者友好型疗法需求的增加，以及缓释药物递送系统的快速创新。

Long-acting formulations are increasingly used in oncology, diabetes, HIV, psychiatric disorders, and cardiovascular diseases, where consistent therapeutic levels are critical for long-term management..

长效制剂在肿瘤学、糖尿病、HIV、精神障碍和心血管疾病中的应用日益广泛，在这些疾病中，维持稳定的治疗水平对于长期管理至关重要。

Rising Burden of Chronic Diseases Fuels Demand for Long-Acting Therapies

慢性病负担加重推动对长效疗法的需求

The worldwide increase in chronic diseases is significantly boosting demand for long-acting drugs. Conditions such as cancer, diabetes, schizophrenia, HIV, and cardiovascular disorders require prolonged treatment regimens, where patient adherence often becomes a major challenge. Long-acting formulations address this issue by reducing dosing frequency and maintaining stable drug concentrations over weeks or months..

全球慢性病的增加显著推动了对长效药物的需求。癌症、糖尿病、精神分裂症、HIV和心血管疾病等状况需要长期的治疗方案，而患者的依从性往往成为一大挑战。长效制剂通过减少给药频率并在数周或数月内维持稳定的药物浓度来解决这一问题。

For instance, the World Health Organization reported nearly 20 million new cancer cases globally in 2022, while diabetes continues to affect more than 500 million people worldwide. This growing patient population is encouraging healthcare providers to adopt therapies that improve convenience and reduce relapse risks..

例如，世界卫生组织报告称，2022年全球新增癌症病例近2000万例，而糖尿病继续影响着全球超过5亿人口。不断扩大的患者群体正促使医疗保健提供者采用能够提高便利性并降低复发风险的治疗方案。

Long-acting injectables and polymer-based depots are increasingly used in psychiatric care, where treatment interruptions can lead to hospitalization. Similarly, HIV prevention therapies such as injectable cabotegravir have transformed adherence patterns by replacing daily oral regimens with bi-monthly dosing schedules..

长效注射剂和聚合物基缓释 depot 在精神科护理中日益得到应用，因为治疗中断可能导致住院。同样，诸如注射用卡博特韦等 HIV 预防疗法通过将每日口服方案替换为每两月一次的给药计划，改变了患者的依从性模式。

Pharmaceutical companies are responding with advanced formulations that enhance bioavailability, extend therapeutic action, and minimize side effects. In 2025, investments in long-acting oncology and CNS therapies accelerated as healthcare systems prioritized improved patient outcomes and lower treatment costs..

制药公司正通过先进制剂作出回应，这些制剂可提高生物利用度、延长治疗作用并最大限度地减少副作用。2025年，随着医疗系统优先改善患者预后并降低治疗成本，对长效肿瘤学和中枢神经系统疗法的投资加速增长。

Get a Free Sample:

获取免费样品：

https://www.persistencemarketresearch.com/samples/34040

Key Highlights

重点摘要

The global long-acting drugs market is projected to grow from US$ 7.2 billion in 2026 to US$ 13.3 billion by 2033, registering a CAGR of 8.9%.

全球长效药物市场预计将从2026年的72亿美元增长至2033年的133亿美元，年复合增长率（CAGR）为8.9%。

Rising prevalence of chronic diseases such as cancer, diabetes, HIV, and CNS disorders is accelerating demand for sustained-release therapies worldwide.

癌症、糖尿病、HIV 和中枢神经系统疾病等慢性病的患病率不断上升，正在加速全球对缓释疗法的需求。

North America leads the market with 41.2% share, supported by advanced healthcare infrastructure and strong pharmaceutical R&D investments.

北美以41.2%的市场份额领先全球，这得益于其先进的医疗基础设施和强劲的制药研发投入。

Asia Pacific is emerging as the fastest-growing region due to expanding healthcare access, increasing patient population, and government support for innovative therapies.

亚太地区正成为增长最快的地区，这得益于医疗保健可及性的扩大、患者群体的增加以及政府对创新疗法的支持。

Microsphere-Based Systems dominate delivery technology adoption because of their controlled drug release capabilities and improved patient adherence.

基于微球的系统因其可控的药物释放能力和提高的患者依从性，在递送技术采用中占据主导地位。

Technological Advancements in Drug Delivery Systems Accelerate Innovation

药物递送系统的技术进步加速创新

Innovation in drug delivery technology is another major driver of the long-acting drugs market. Pharmaceutical companies are developing advanced systems such as microspheres, liposomes,

药物递送技术的创新是长效药物市场的另一大驱动因素。制药公司正在开发微球、脂质体等先进系统，

biodegradable implants

可生物降解植入物

, and polymer depots to deliver controlled and sustained drug release.

，以及用于实现药物控释和缓释的聚合物储库。

Microsphere-based systems remain the dominant technology because they provide precise release profiles and improve drug stability. These formulations are widely used in oncology, hormonal therapies, and central nervous system disorders due to their ability to maintain therapeutic effectiveness for extended periods..

微球系统因其能够提供精确的释放曲线并提高药物稳定性，仍然是主导技术。这些制剂由于能够在较长时间内维持治疗效果，被广泛应用于肿瘤学、激素疗法和中枢神经系统疾病的治疗中。

The rise of oral long-acting biologics also represents a transformative opportunity. Technologies using permeation enhancers and protective coatings are enabling peptide-based therapies to survive gastric degradation and maintain bioavailability. Products such as oral semaglutide and next-generation .

口服长效生物制剂的兴起也代表着一个变革性的机遇。利用渗透增强剂和保护涂层的技术，使得基于肽的疗法能够抵御胃部降解并保持生物利用度。诸如口服司美格鲁肽和下一代产品等。

GLP-1

胰高血糖素样肽-1

therapies demonstrate how sustained-release technologies are expanding beyond injectables.

这些疗法表明，缓释技术正逐渐超越注射剂的范畴。

Manufacturers are also investing in sensor-enabled delivery systems and

制造商也在投资配备传感器的递送系统，并

smart packaging solutions

智能包装解决方案

that improve dose tracking and patient monitoring. These innovations support adherence while helping healthcare providers optimize treatment plans through real-time data collection.

这些创新有助于改善剂量追踪和患者监测，在通过实时数据收集帮助医疗保健提供者优化治疗方案的同时，提高患者的依从性。

Key Highlight: Eli Lilly Advances Oral

重点亮点：礼来公司推进口服药物研发

GLP-1

Innovation in 2025

2025年的创新

A standout event in 2025 was the advancement of Eli Lilly and Company's oral

2025年的一大亮点事件是礼来公司口服药物的进展

GLP-1

receptor agonist, orforglipron, following successful Phase III clinical trial results in diabetes and obesity management. According to the company, the therapy demonstrated statistically significant improvements in blood sugar control and body weight reduction across multiple late-stage studies involving adults with type 2 diabetes and obesity..

受体激动剂orforglipron在糖尿病和肥胖管理的III期临床试验中取得成功后。据该公司称，该疗法在涉及患有2型糖尿病和肥胖的成年人的多项后期研究中，显示出在血糖控制和体重减轻方面的统计学显著改善。

The development highlighted growing industry interest in oral alternatives to injectable

这一进展凸显了业界对注射剂口服替代方案日益增长的兴趣

GLP-1

therapies. Eli Lilly stated that orforglipron is a once-daily oral small-molecule

疗法。礼来公司表示，orforglipron 是一种每日一次口服的小分子

GLP-1

胰高血糖素样肽-1

receptor agonist designed without food and water intake restrictions, differentiating it from existing oral

一种无需限制饮食和饮水的受体激动剂，使其区别于现有的口服

GLP-1

treatments. In one Phase III study, the drug showed superior efficacy compared with oral semaglutide in reducing A1C and body weight.

治疗。在一项III期研究中，该药物在降低糖化血红蛋白（A1C）和体重方面显示出优于口服司美格鲁肽的疗效。

The innovation also reflects increasing commercial focus on expanding obesity and diabetes treatment access through convenient oral therapies. Reuters reported that Eli Lilly expected obesity trial results for orforglipron during 2025 as demand for

这一创新也反映出，业界正日益注重通过便捷的口服疗法来扩大肥胖症和糖尿病治疗的可及性。据路透社报道，随着对

GLP-1

therapies continued to surge globally. Additional media reports noted that the company aimed to pursue regulatory approvals following positive trial outcomes.

疗法在全球范围内持续激增。更多媒体报道指出，该公司旨在在试验结果积极后寻求监管批准。

This development signals a broader transition toward patient-focused chronic disease therapies that prioritize ease of administration and long-term treatment adherence. The progress of oral

这一进展标志着向以患者为中心的慢性病疗法更广泛的转变，这些疗法优先考虑给药的便捷性和长期治疗依从性。口服药物的进展

GLP-1

胰高血糖素样肽-1

medicines is expected to intensify competition within diabetes and obesity management markets, encouraging further investments in next-generation oral metabolic therapies.

预计药物将加剧糖尿病和肥胖症管理市场的竞争，从而推动对下一代口服代谢疗法的进一步投资。

Request a Customization:

申请定制：

https://www.persistencemarketresearch.com/request-customization/34040

Segmentation Insights: Microsphere-Based Systems Lead Delivery Technology Segment with Superior Sustained-Release Performance

细分洞察：微球系统凭借卓越的缓释性能，领跑递送技术领域

Microsphere-Based Systems dominate the delivery technology segment of the long-acting drugs market due to their ability to provide controlled and sustained drug release, improving therapeutic effectiveness and patient compliance. These biodegradable polymer particles gradually release active ingredients over weeks or months, significantly reducing dosing frequency in chronic disease treatments.

微球系统在长效药物市场的递送技术领域占据主导地位，这得益于其能够提供可控且持续的药物释放，从而提高治疗效果和患者依从性。这些可生物降解的聚合物颗粒在数周或数月内逐渐释放活性成分，显著降低了慢性疾病治疗中的给药频率。

The technology is widely used across oncology, hormonal therapies, CNS disorders, and .

该技术广泛应用于肿瘤学、激素疗法、中枢神经系统疾病等领域。

infectious disease management

传染病管理

because of its versatility and compatibility with injectable formulations. Microspheres also improve drug stability, bioavailability, and targeted delivery while minimizing side effects. Strong regulatory familiarity, expanding clinical adoption, and continuous advancements in biodegradable polymer technologies further strengthen their leadership position in the global long-acting drugs market..

凭借其多功能性以及与注射制剂的兼容性。微球还能提高药物稳定性、生物利用度和靶向递送能力，同时最大限度地减少副作用。监管机构对其高度熟悉、临床应用不断扩大，以及可生物降解聚合物技术的持续进步，进一步巩固了其在全球长效药物市场中的领先地位。

Regional Insights: North America Leads Long-Acting Drugs Market While Asia Pacific Emerges as Fastest-Growing Regional Hub

区域洞察：北美主导长效药物市场，而亚太地区成为增长最快的区域中心

North America holds the largest share of the long-acting drugs market, accounting for about 41.2% of global value, supported by strong pharmaceutical R&D activity, advanced healthcare infrastructure, and favorable regulatory approvals. The U.S. dominates regional demand due to increasing adoption of long-acting injectables in oncology, diabetes, schizophrenia, and HIV therapies.

北美占据长效药物市场的最大份额，约占全球价值的41.2%，这得益于强劲的医药研发活动、先进的医疗基础设施以及有利的监管审批。美国在区域需求中占据主导地位，原因是长效注射剂在肿瘤学、糖尿病、精神分裂症和HIV治疗中的应用日益广泛。

FDA approvals for sustained-release formulations and strong reimbursement policies continue to strengthen market expansion..

FDA对缓释制剂的批准以及强有力的报销政策持续推动市场扩张。

Asia Pacific is the fastest-growing region. China and India are leading regional growth due to rising chronic disease prevalence, improving healthcare access, and expanding

亚太地区是增长最快的地区。由于慢性病患病率上升、医疗可及性改善以及不断扩张，中国和印度引领着该地区的增长。

pharmaceutical manufacturing

药品制造

capabilities. Government healthcare initiatives and growing investments in drug delivery innovation are encouraging adoption of long-acting therapies across large patient populations.

能力。政府的医疗保健倡议以及对药物递送创新日益增长的投资，正在推动长效疗法在广大患者群体中的普及应用。

Europe follows with strong growth supported by aging populations, increasing clinical trial activity, and investments in advanced drug delivery technologies. Regulatory support from the European Medicines Agency and funding initiatives focused on innovative therapeutics continue to strengthen the region's position..

欧洲紧随其后，在人口老龄化、临床试验活动增加以及对先进药物递送技术投资的推动下，实现了强劲增长。欧洲药品管理局的监管支持以及专注于创新疗法的资助计划，持续巩固了该地区在这一领域的地位。

Key Players and Business Strategies

关键参与者与商业策略

Leading players include Eli Lilly and Company, ViiV Healthcare, Johnson & Johnson, Novartis AG, and AstraZeneca plc.

主要参与者包括礼来公司、ViiV Healthcare、强生公司、诺华公司和阿斯利康公司。

Eli Lilly is expanding its metabolic disease portfolio through advanced oral

礼来公司正通过先进的口服药物扩大其代谢疾病产品组合

GLP-1

胰高血糖素样肽-1

therapies and sustained-release drug delivery innovation targeting diabetes and obesity treatment.

针对糖尿病和肥胖症治疗的疗法及缓释药物递送创新。

ViiV Healthcare focuses on long-acting HIV prevention and treatment solutions, strengthening its position through injectable therapies that improve patient adherence and reduce dosing frequency.

ViiV Healthcare 专注于长效 HIV 预防和治疗解决方案，通过提高患者依从性并减少给药频率的注射疗法，巩固其市场地位。

Johnson & Johnson continues investing in long-acting psychiatric therapies, particularly injectable antipsychotics designed to improve treatment persistence in schizophrenia management.

强生公司持续投资长效精神疾病疗法，特别是旨在提高精神分裂症治疗依从性的注射用抗精神病药物。

Novartis is strengthening oncology-focused sustained-release formulations and precision medicine initiatives to improve therapeutic effectiveness across chronic conditions.

诺华正在加强以肿瘤学为重点的缓释制剂和精准医疗举措，以提高慢性疾病的治疗效果。

AstraZeneca is investing in biologic delivery technologies and strategic partnerships aimed at enhancing long-term treatment outcomes in cardiovascular and metabolic diseases.

阿斯利康正在投资生物制剂递送技术并建立战略合作伙伴关系，旨在改善心血管和代谢性疾病的长期治疗结果。

Strategies across the industry emphasize advanced delivery technologies, expansion of chronic disease portfolios, patient-centric formulations, and partnerships supporting innovation in sustained-release therapeutics.

全行业战略均强调先进递送技术、慢性病产品组合扩张、以患者为中心的制剂开发，以及支持缓释疗法创新的合作伙伴关系。

Buy Now

立即购买

：

https://www.persistencemarketresearch.com/checkout/34040

Market Segmentation

市场细分

By Delivery Technology

按配送技术

Liposome-Based Systems

基于脂质体的系统

Microsphere-Based Systems

基于微球的系统

Polymer-Based Depots

聚合物基储库

In-Situ Forming Gels

原位形成凝胶

Nanoparticle-based systems

基于纳米颗粒的系统

By Route of Administration

按给药途径

Injectable

可注射的

Implant

植入物

Oral

口头

By Therapeutic Area

按治疗领域

Cancer

癌症

Central Nervous System (CNS) Disorders

中枢神经系统（CNS）疾病

Hormone Disorders

激素紊乱

Infectious Diseases

传染病

Pain Management

疼痛管理

Contraception

避孕

By Material Used

按所用材料

Polymer

聚合物

Non-Polymer

非聚合物

By Distribution Channel

按分销渠道

Hospital Pharmacies

医院药房

Retail Pharmacies

零售药店

Online Pharmacies

网上药店

Specialty Clinics

专科诊所

By Region

按地区

North America

北美洲

Europe

欧洲

East Asia

东亚

South Asia & Oceania

南亚与大洋洲

Latin America

拉丁美洲

Middle East and Africa

中东和非洲

Get More Insights — Related

获取更多见解 — 相关

Healthcare Market Reports

医疗保健市场报告

：

Sterile Injectable Drugs Market

无菌注射药物市场

by Product Type (Large, Small Molecule), Drug Class (Monoclonal Antibodies, Cytokines, Insulin), Administration Route (Intradermal, Intramuscular), Dosage Form, and Regional Analysis for 2025 – 2032

按产品类型（大分子、小分子）、药物类别（单克隆抗体、细胞因子、胰岛素）、给药途径（皮内、肌肉注射）、剂型以及2025–2032年区域分析

U.S. Antipsychotic Drugs Market

美国抗精神病药物市场

by Disease (Schizophrenia, Bipolar Disorder, Others), Therapeutic Class (First Generation, Second Generation, Third Generation), Distribution Channel (Hospital Pharmacies, Others), and Zone Analysis 2026 – 2033

按疾病（精神分裂症、双相情感障碍、其他）、治疗类别（第一代、第二代、第三代）、分销渠道（医院药房、其他）及区域分析，2026–2033年

Medical Marijuana Market

医用大麻市场

by Product Type (Flowers, Edibles, Concentrates, Others), Application (Chronic Pain, Cancer, Mental Disorders, Others), End-user (Research & Development, Pharmaceutical), and Regional Analysis for 2026 – 2033

按产品类型（花卉、食用产品、浓缩物、其他）、应用领域（慢性疼痛、癌症、精神障碍、其他）、终端用户（研发、制药）以及2026年至2033年的区域分析

Injectable Drug Delivery Market

注射药物递送市场

by Device Type (Conventional Injection Devices, Prefilled Syringes, Auto-Injectors, Others), Route of Administration (Intravenous, Intramuscular, Subcutaneous), End-user (Hospitals & Clinics, Home Care Settings, Others), and Regional Analysis for 2026 – 2033

按设备类型（传统注射装置、预充式注射器、自动注射器、其他）、给药途径（静脉注射、肌肉注射、皮下注射）、最终用户（医院与诊所、家庭护理环境、其他）以及2026年至2033年的区域分析

Metered Dose Inhalers Market

定量吸入器市场

by Inhaler Type (Standard Metered Dose Inhalers, Others), Disease Type (Asthma, COPD, Others), Medication Type (Reliever Inhalers, Preventive Inhalers, Combination Therapy Inhalers), and Regional Analysis for 2026 – 2033

按吸入器类型（标准定量吸入器、其他）、疾病类型（哮喘、慢性阻塞性肺病、其他）、药物类型（缓解型吸入器、预防型吸入器、联合治疗吸入器）以及2026年至2033年的区域分析

Diabetic Nephropathy Market

糖尿病肾病市场

by Drug Class (ACE Inhibitors, Angiotensin Receptor Blockers, SGLT2 Inhibitors, Others), Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Others), and Regional Analysis for 2026 – 2033

按药物类别（ACE抑制剂、血管紧张素受体阻滞剂、SGLT2抑制剂、其他）、分销渠道（医院药房、药店和零售药房、其他）以及2026-2033年的区域分析

Low and Middle Income Countries Opioid Substitution Therapy Market

中低收入国家阿片类药物替代治疗市场

by Drug Class (Opioid Antagonists, Opioid Agonists and Partial Agonists), Indication (Pain Management, Opioid Withdrawal/Opioid Use Disorder (OUD), Others), and Regional Analysis for 2026 – 2033

按药物类别（阿片受体拮抗剂、阿片受体激动剂及部分激动剂）、适应症（疼痛管理、阿片戒断/阿片使用障碍（OUD）、其他）以及2026–2033年区域分析

Giant Cell Arteritis Treatment Market

巨细胞动脉炎治疗市场

by Treatment Type (Corticosteroid Therapy, Immunosuppressive Agents, Anticoagulants, and Monoclonal Antibodies), Route of Administration (Oral, Intravenous, and Subcutaneous), and Regional Analysis for 2026 – 2033

按治疗类型（皮质类固醇疗法、免疫抑制剂、抗凝剂和单克隆抗体）、给药途径（口服、静脉注射和皮下注射）以及2026-2033年的区域分析

Ciprofloxacin Market

环丙沙星市场

by Dosage Form (Powder, Suspension, Tablet, Eye drops, Intravenous preparation) Application (Urinary tract infections, Lower respiratory infections, Nosocomial pneumonia, Others), and Regional Analysis for 2026 – 2033

按剂型（粉剂、混悬剂、片剂、滴眼液、静脉注射制剂）、适应症（尿路感染、下呼吸道感染、医院获得性肺炎、其他）以及2026–2033年区域分析

Drug-Resistant Tuberculosis Market

耐药结核病市场

by Drug Class (Amoxicillin/Clavulanate, Bedaquiline, Carbapenems with Clavulanic Acid, Clofazimine, Others), Disease Type (Active TB, Latent TB), Treatment Type, Distribution Channel, and Regional Analysis for 2026 - 2033

按药物类别（阿莫西林/克拉维酸、贝达喹啉、含克拉维酸的碳青霉烯类、氯法齐明、其他）、疾病类型（活动性结核病、潜伏性结核病）、治疗类型、分销渠道以及2026-2033年区域分析

About

关于

Persistence Market Research

：

At Persistence Market Research, we are pioneers in Market Research and Consulting, bringing you the most dynamic insights into market trends, consumer behaviours, and competitive intelligence! For over a decade, we've been at the forefront of delivering game-changing analytics and research that drive businesses toward growth..

在Persistence Market Research，我们是市场研究和咨询领域的先驱，为您提供关于市场趋势、消费者行为和竞争情报的最具活力的洞察！十多年来，我们始终处于提供变革性分析和研究的前沿，推动企业实现增长。

Our extensive market report database is a go-to resource for Fortune 500 companies, savvy business investors, media and entertainment channels, and academic institutions, empowering them to navigate the global and regional business landscape with confidence. With thousands of statistics and in-depth analyses covering over 20 diverse industries across 25 major countries, we provide the insights you need to succeed in today's competitive environment..

我们庞大的市场报告数据库是财富500强企业、精明的商业投资者、媒体与娱乐频道以及学术机构的首选资源，助力他们自信地驾驭全球及区域商业格局。凭借涵盖25个主要国家、20多个多元化行业的数千项统计数据和深度分析，我们为您提供在当今竞争环境中取得成功所需的洞察。

Contact

联系

Ankush Nikam

安库什·尼卡姆

Persistence Market Research

Second Floor, 150 Fleet Street, London, EC4A 2DQ

伦敦舰队街150号二楼，邮编EC4A 2DQ

+44 203-837-5656

United Kingdom

英国

USA Phone - +1 646-878-6329